Published in Lab Business Week, February 6th, 2005
In this final tranche, Fusion bought 4.8 million shares of Aastrom's common stock for gross proceeds of $12 million at an average price of $2.50 per share, a premium to the closing price of $2.38 per share.
This completes the $24 million common stock purchase agreement between Aastrom and Fusion.
Our issuance of these shares to Fusion was not registered under the Securities Act of 1933. The resale by Fusion of the shares...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.